Spots Global Cancer Trial Database for Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer
Official Title: A Phase II Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer
Study ID: NCT01540071
Conditions
Interventions
Study Description
Brief Summary: This study is to evaluate the benefits of investigational drug, NRX 194204 in slowing down/stopping/reversing progression of the castration resistant and taxane resistant prostate cancer.
Detailed Description: Numerous studies in pre-clinical models and in human clinical trials have clearly established the potential for the use of rexinoids in the treatment and prevention of cancer. NRX 194204, a second generation rexinoid, is a highly potent and specific activator of RXRs (retinoid X receptors). Because NRX 194204 is significantly more selective for the RXRs relative to the RARs (retinoic acid receptors) than a first generation approved drug, it is associated with fewer adverse events in clinical use. This study seeks to investigate NRX 194204 monotherapy in patients with castration- and taxane- resistant prostate cancer.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Lalita Pandit, MD, Fountain Valley, California, United States
Contact Details
Name: Lalita Pandit, MD
Affiliation: Lalita Pandit, MD
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
